ROP drug granted orphan designation
Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.
Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.
The orphan designation entitles Premacure to assistance and reduced fees for pre- and post-authorization activities.
Iplex is currently approved in the US for the treatment of growth failure in children. Premacure intends to launch a multicentre Phase II trial of Iplex in the ROP indication during the second quarter of this year, and to continue investigating the drug for other indications.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
